The pharmaceutical composition for preventing and treating autoimmune disease of the present disclosure may be used alone or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, biological response modifiers or therapeutic agents for autoimmune disease. As described above, whereas ...
Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, antigen-binding fragments thereof, and a cleavable linker. Methods of use of said ADCs are also des
modifiers, such as acylating agents and esterifying agents, in an attempt to increase their proteolytic cleavage resistance. The additional cross-linking of collagen materials and hyaluronic acid has also been suggested for purposes including increasing viscosity and potentially increasing the material's...
According to some embodiments of the invention, the compositions described herein may include other additives, including, but not limited to, catalysts, UV absorbers, fillers, plasticizers, blowing agents, rheology modifiers, viscosity enhancers, adhesion promoters and those described in U.S. Patent Ap...
According to some embodiments of the invention, the compositions described herein may include other additives, including, but not limited to, catalysts, UV absorbers, fillers, plasticizers, blowing agents, rheology modifiers, viscosity enhancers, adhesion promoters and those described in U.S. Patent Ap...